AVTX
Avalo Therapeutics, Inc. · Healthcare
16.27
8.39%(-1.49)
Prev. Close19.00
16.78%(+2.73)
Pre-marketLast Updated: — ET
52W L: $3.3952W H: $20.72
$17.00
CHG-0.67 (-3.79%)
H$18.75
L$13.07
VOL13M
AVTX (1h)
Avalo Therapeutics, Inc. · Healthcare
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline the first results. All of the major U.S. indices saw wild swings on Thursday, and after opening the day deep in the red,... Here Are Monday's Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the firm's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $16.00, for a total value of $10,864.00. Following the completion of the transaction, the insider owned 3,622 shares in the company,
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and year-end financial results for 2025.
Sullivan Christopher Ryan
officer: Chief Financial Officer
500 SH @ $15.86
2026-04-01
Sullivan Christopher Ryan
officer: Chief Financial Officer
7,479 SH @ $16.83
2026-04-01
Sullivan Christopher Ryan
officer: Chief Financial Officer
6,200 SH @ $17.02
2026-04-02
Sullivan Christopher Ryan
officer: Chief Financial Officer
1,780 SH @ $17.57
2026-04-02
Doyle Mittie
officer: Chief Medical Officer
679 SH @ $8.04
2026-04-01
Doyle Mittie
officer: Chief Medical Officer
679 SH @ $8.04
2026-04-01
Doyle Mittie
officer: Chief Medical Officer
679 SH @ $16.00
2026-04-01
Jain Rita
director
1,339 SH @ $14.93
2026-03-31